Joshua Kealey

Joshua Kealey

Auto-generated profile, based on publicly available information

Joshua Kealey

Department of Urology Eastern Health Melbourne Victoria Australia

Research Focus & Metrics

Academic Career Length

9Years (2018-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
20 November 2021 in BJU International
Verified
Journal Article
Open access
PDF file
CIChristopher C.K. Ip
Christopher C.K. Ip
JKJoshua Kealey
Joshua Kealey
IDIan D. Davis
Ian D. Davis
SSShomik Sengupta
Shomik Sengupta
Healthcare utilisation has changed due to the COVID-19 pandemic. Many studies have reported a reduction in services such as cancer detection and treatment, and a reduction in patient participation in cancer early detection programmes (1). As the pandemic continues, there are concerns that service disruptions due to the pandemic response may lead to reduced referrals, “missed” care and presentations of malignancies at more advanced stage.

31 March 2023 in Asia-Pacific Journal of Clinical Oncology
Verified
Journal Article
Open access
JKJoshua Kealey
Joshua Kealey
CIChristopher Ip
Christopher Ip
IDIan D. Davis
Ian D. Davis
SSShomik Sengupta
Shomik Sengupta
Introduction: Patient presentation at multidisciplinary cancer meetings (MDMs) is a key quality indicator in cancer care and may have particular utility in rare malignancies, such as upper tract urothelial carcinoma (UTUC). This study aims to investigate what proportion of patients diagnosed with UTUC had treatment intent changed at MDM, the nature of these changes, and what patient factors may correlate with a suggested change.Methods: This study analyzed patients diagnosed with UTUC between 2015 and 2020 at an Australian tertiary referral center. MDM discussion rate and suggested treatment intent changes were analyzed. Patient factors that may prompt change, including age, estimated glomerular filtration rate (eGFR), Charlson Comorbidity Index (CCI), and Eastern Cooperation Oncology Group performance status (ECOG PS), were assessed.Results: Seventy‐five patients were diagnosed with UTUC of whom 71 (94.6%) were discussed at an MDM upon diagnosis. Change to palliative intent was suggested in 8/71 (11%) patients. Patients for whom change to palliative treatment was suggested had a higher age (median 85 vs. 78 years, p<.01), CCI (median 7 vs. 4, p<.005), ECOG PS (median 2 vs. 0, p<.002), and lower eGFR (mean 31 vs. 66 mL/min/1.73 m2, p< .0001), compared to those who underwent radical treatment. No patient had an MDM recommendation to change from palliative to curative treatment.Conclusion: MDM discussion resulted in clinically important changes of treatment intent in a substantial proportion of patients with UTUC, potentially sparing futile treatments. Several patient factors were associated with suggested changes, highlighting the requirement for accurate, in‐depth patient information at MDM discussion.

1 September 2018 in Urology Case Reports
Verified
Journal Article
Open access
JKJoshua Kealey
Joshua Kealey
HYHenry H.I. Yao
Henry H.I. Yao
JGJeremy Grummet
Jeremy Grummet

19 December 2024 in BJUI Compass
Verified
Journal Article
Open access
WCWilliam Chui
William Chui
JKJoshua Kealey
Joshua Kealey
HYHenry H. Yao
Henry H. Yao
GCGarson Chan
Garson Chan
ABAlvaro Bazo
Alvaro Bazo
JGJohan Gani
Johan Gani
Objectives: To assess long‐term outcomes (up to 10 cycles) of repeated intradetrusor botulinum toxin (BoNT) utilisation in multiple sclerosis (MS) and idiopathic overactive bladder (OAB).Materials and Methods: This is a retrospective, international, multi‐centre, observational cohort study of patients diagnosed with MS and neurogenic OAB and treated with intradetrusor BoNT between January 2005 and January 2020 (just prior to COVID‐19 interruption). Dose, efficacy, duration of effect, International Consultation on Incontinence Questionnaire Overactive Bladder (ICIQ‐OAB) and International Consultation on Incontinence Questionnaire Urinary Incontinence (ICIQ‐UI) measures and complication rates were recorded. Comparisons were made to those with idiopathic OAB.Results: Seven hundred and ninety‐two patients received intradetrusor BoNT treatment (104 had MS with neurogenic OAB and 688 had idiopathic OAB). Patients with MS were more likely to receive higher doses of BoNT in all cycles. Self‐reported efficacy ranged from 85.7 to 100% (MS) and 87.2 to 100% (idiopathic) with MS patients reporting increased efficacy in cycles 1–3 comparatively (p < 0.05). Duration of effect ranged from 4.5 to 9 months with a reduction in the MS cohort between cycles 1 and 10 (median 8 months vs. 5 months, p = 0.0156).Conclusion: Patients with MS and neurogenic OAB have a good therapeutic effect from intradetrusor BoNT that is sustained over at least 10 cycles with significant reduction in the duration of action with subsequent cycles.

24 June 2025 in BJUI Compass
Verified
Journal Article
Open access
WCWilliam Chui
William Chui
ABAlvaro Bazo
Alvaro Bazo
HYHenry H. Yao
Henry H. Yao
JKJoshua Kealey
Joshua Kealey
LPLana Pepdjonovic
Lana Pepdjonovic
RPRichard Parkinson
Richard Parkinson
Objectives: This study aims to explore the impact of age on long‐term outcomes associated with intradetrusor botulinum toxin (BoNT) usage (up to four cycles) in elderly patients with refractory overactive bladder syndrome (OAB).Materials and Methods: We conducted a retrospective observational cohort study across institutions in Nottingham (UK) and Melbourne (Australia). Patients with refractory OAB and treated with intradetrusor BoNT between January 2005 and January 2020 were stratified into age groups: ≤40, 40–49, 50–59, 60–69 and ≥70 years. Efficacy was defined as patient self‐reported improvement in symptoms post‐BoNT injection. Duration of effect was time (months) between BoNT injection to patient reported onset of symptom recurrence. Data on BoNT type and dosing, urinary tract infection (UTI), urinary retention, ICIQ‐OAB and International Consultation on Incontinence Questionnaire Urinary Incontinence (ICIQ‐UI) questionnaires were also collected. Statistical analyses were conducted with SPSS® 25 software. P‐value < 0.05 was considered statistically significant.Results: There were 943 patients stratified into age groups: < 40 (183), 40–49 (150), 50–59 (173), 60–69 (219) and ≥ 70 (218). Median age was 58 (IQR 44–69). Most patients were female 724/943 (76.8%). From Cycles 1 to 4, age group ≥ 70 efficacy rates were 85.1%, 84.1%, 92.6% and 89.3%. Corresponding median duration of effect (months) were 6.8, 8.0, 7.0 and 8.0. For Cycle 2; age ≥ 70 was a predictor of reduced efficacy (P = 0.004). Neurogenic causes of OAB were predictors of increased efficacy for Cycles 2 (P = 0.004) and 3 (P = 0.0145). Men had higher rates of urinary retention than women in Cycles 1 (42.4% vs 29.3%, P = 0.003) and 2 (37.9% vs 23.0%, P = 0.0018). All age groups showed improvement in patient‐reported outcome measures (PROMs) post‐BoNT injection.Conclusion: In elderly patients with refractory OAB and treated with intradetrusor BoNT (up to four cycles), age ≥ 70 was an independent predictor for reduced BoNT efficacy (84.1%) in Cycle 2.